生命科学资讯

Angelini nocks an AI arrow with $120M Quiver Bioscience deal

UPDATED: FDA illuminates new approval pathway for bespoke gene editing therapies

Swiss Rockets buys MGI subsidiary Complete Genomics after Biosecure Act

Fortress to sell priority review voucher for $205M

Novo’s next-gen obesity shot fails to match Lilly drug in head-to-head study

FDA unveils long-awaited guidance on new pathway for individualized therapies

Flagship's Generate targets $2B+ valuation with Nasdaq IPO

AbbVie budgets $380M for obesity and neuroscience API facilities in Chicago

FDA issues safety alert on Trividia blood glucose monitors

Generate plans $425M IPO to bankroll antibody's phase 3 asthma trials

Gossamer's stock sinks after phase 3 pulmonary arterial hypertension fail

Frontier, Harbour do licensing deals with GSK, Solstice

A federal experiment opens up a new market for digital health — if it works

Gilead brings Arcellx fully under the fold

Vanda gets FDA nod for atypical antipsychotic Bysanti

Biggest gainers and losers for Feb. 16-20, 2026

Roche to stop work on bone health treatment for Duchenne

Merck reorganizes; Blackstone to fund trials for J&J drug

First test of gene therapy for rare form of autism is underway

Could sleep engineering be used to combat PTSD and depression?